Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter : a cross-sectional study
OBJECTIVES: Available data on the prevalence of hepatic steatosis in an unselected HIV-infected population are limited. The aim of this study was to determine the prevalence of hepatic steatosis and assess the associated factors in HIV-infected individuals.
PATIENTS AND METHODS: One hundred and thirty-six HIV-infected individuals were enrolled in this cross-sectional study. Patients underwent transient elastography and controlled attenuation parameter (CAP) measurements. We analyzed the associations between the CAP value and demographic, metabolic, and immunologic parameters. For the first time, in HIV-infected individuals, we used a continuous scale of CAP values to identify significant covariates of hepatic fat accumulation. As a result and compared with other methods, one of the main advantages of CAP was that the quantitative measurement of liver steatosis could be used for analysis.
RESULTS: Using univariate analysis, CAP was significantly correlated with the following continuous variables: CD4 percentage (P=0.035), CD8 percentage (P=0.016), age (P<0.001), CD4/8 ratio (P=0.002), BMI (P<0.001), serum triglyceride (P<0.001), and serum cholesterol (P=0.004) levels, the length of known HIV positivity (P<0.001), and liver stiffness (P=0.041). With respect to categorical variables, a significant association was found for the presence of diabetes (P=0.006), hypertension (P<0.001), facial lipodystrophy (P=0.031), and the use of lopinavir (P=0.042). In multivariate analysis using linear regression, BMI (P<0.001), presence of diabetes (P=0.026), and hypertension (P=0.040) were identified as independent significant correlates. Darunavir therapy was associated negatively with the CAP value (P=0.032).
CONCLUSION: Our findings reflect the importance of metabolic factors in hepatic steatosis. The strongest independent covariate was BMI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
European journal of gastroenterology & hepatology - 27(2015), 6 vom: 27. Juni, Seite 679-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sulyok, Mihály [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
97C5T2UQ7J |
|---|
| Anmerkungen: |
Date Completed 22.02.2016 Date Revised 18.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MEG.0000000000000339 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM248531891 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM248531891 | ||
| 003 | DE-627 | ||
| 005 | 20231224151616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MEG.0000000000000339 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0828.xml |
| 035 | |a (DE-627)NLM248531891 | ||
| 035 | |a (NLM)25923943 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sulyok, Mihály |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter |b a cross-sectional study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2016 | ||
| 500 | |a Date Revised 18.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Available data on the prevalence of hepatic steatosis in an unselected HIV-infected population are limited. The aim of this study was to determine the prevalence of hepatic steatosis and assess the associated factors in HIV-infected individuals | ||
| 520 | |a PATIENTS AND METHODS: One hundred and thirty-six HIV-infected individuals were enrolled in this cross-sectional study. Patients underwent transient elastography and controlled attenuation parameter (CAP) measurements. We analyzed the associations between the CAP value and demographic, metabolic, and immunologic parameters. For the first time, in HIV-infected individuals, we used a continuous scale of CAP values to identify significant covariates of hepatic fat accumulation. As a result and compared with other methods, one of the main advantages of CAP was that the quantitative measurement of liver steatosis could be used for analysis | ||
| 520 | |a RESULTS: Using univariate analysis, CAP was significantly correlated with the following continuous variables: CD4 percentage (P=0.035), CD8 percentage (P=0.016), age (P<0.001), CD4/8 ratio (P=0.002), BMI (P<0.001), serum triglyceride (P<0.001), and serum cholesterol (P=0.004) levels, the length of known HIV positivity (P<0.001), and liver stiffness (P=0.041). With respect to categorical variables, a significant association was found for the presence of diabetes (P=0.006), hypertension (P<0.001), facial lipodystrophy (P=0.031), and the use of lopinavir (P=0.042). In multivariate analysis using linear regression, BMI (P<0.001), presence of diabetes (P=0.026), and hypertension (P=0.040) were identified as independent significant correlates. Darunavir therapy was associated negatively with the CAP value (P=0.032) | ||
| 520 | |a CONCLUSION: Our findings reflect the importance of metabolic factors in hepatic steatosis. The strongest independent covariate was BMI | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Triglycerides |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Makara, Mihály |e verfasserin |4 aut | |
| 700 | 1 | |a Rupnik, Zsófia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferenci, Tamás |e verfasserin |4 aut | |
| 700 | 1 | |a Újhelyi, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Kormos, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Gerlei, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Szlávik, János |e verfasserin |4 aut | |
| 700 | 1 | |a Horváth, Gábor |e verfasserin |4 aut | |
| 700 | 1 | |a Vályi-Nagy, István |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of gastroenterology & hepatology |d 1996 |g 27(2015), 6 vom: 27. Juni, Seite 679-85 |w (DE-627)NLM074735322 |x 1473-5687 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2015 |g number:6 |g day:27 |g month:06 |g pages:679-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MEG.0000000000000339 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2015 |e 6 |b 27 |c 06 |h 679-85 | ||